Purification and Antiangiogenic Activity Assay of Recombinant Human Angiostatin

卢文菊,张晓实,罗进贤,陈柏铭
DOI: https://doi.org/10.3969/j.issn.1008-1836.2001.02.002
2001-01-01
Abstract:Objective: To purify the recombinant human angiostatin (rhAGN) produced by engineered E. coli and to determine its antiangiogenic activity. Methods: rhAGN was purified with ultrasonication and Sephadex G-100 gel filtration. Lowry' S method was used to determine the protein concentration. The purity of rhAGN was analyzed by SDS-PAGE and photodensitometry scanning. MTT method was applied in the determination of the effect of rhAGN on the proliferation of human dermal microvascular endothelial cell line HDMEC. Modified CAM technique was used to determine the inhibitory effect of rhAGN on angiogenesis in 6-day-old chicken CAM induced by 30ng bFGF. Results: (1) The purity of rhAGN was 96%, with total recovery of 61. 7%. (2) Within the concentration range of 0. 1 ~3. 0 mg/L, rhAGN inhibited the proliferation of HDMEC stimulated by 10 μg/L EGF in a dose-dependent style. The maximum inhibitory dose was approximately 2. 0 mg/L with the inhibition rate of 92. 3%, and the half- maximum inhibition dose was around 1. 0 mg/L; (3 ) When administration of rhAGN at 100 μg/embryo and 200 μg/embryo, the amount of capillary microvasculars of chicken CAM under the testing disc were 79 ± 23(n= 5 ) and 37 ± 11 (n = 5 ) respectively and both were significantly less than that of the PBS control group(145±36, n= 5) (P<0. 01 ). Conclusion: rhAGN expressed by E. coli was highly purified. It was demonstrated that the purified rhAGN had the inhibitory effect on endothelial cell proliferation and had antiangiogenic activity.
What problem does this paper attempt to address?